Latest Production Development News

Yowie Group’s Q2 FY25 results reveal a mixed performance with a 33% revenue drop in North America offset by growth in Australia and ongoing cost optimisation efforts.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

Investor Centre Limited’s December quarter report reveals a strategic pivot with the withdrawal of its capital raising prospectus, the appointment of a new director, and ongoing talks to expand its wholesale financial services.

Micro-X announces a strategic pivot towards medical imaging, anchored by a $25 million US government contract to develop a portable Full Body CT scanner, while discontinuing its Argus security operations to streamline costs.

Atomos Limited reported a 7% increase in Q2 FY25 sales driven by its core Shinobi II product, but faced margin pressures due to discounting and competitive pricing. The company is finalizing a cost restructure and reviewing funding options to support future growth.

Cadoux Limited reports significant progress in its high purity alumina and Minhub rare earths projects, alongside robust environmental, social, and governance initiatives.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

HydraLyte USA has completed the divestiture of its non-US assets, wiping out debt and boosting cash reserves to US$3.2 million, while focusing its growth strategy on the US ecommerce market with a 28% quarterly revenue increase.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

RooLife Group (ASX: RLG) reported a striking 144% increase in sales revenue for Q2 FY2025, driven by the launch of new online stores across China, Hong Kong, Australia, and India. The company is investing heavily in product development and marketing to capitalize on booming health and wellness markets.

Pure Resources Limited has made significant strides in its Reedy Creek Garnet Project, expanding the resource and delivering promising metallurgical test results that highlight the project's commercial potential.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.